From mega-round to $172M IPO in weeks, Or­chard is bundling cash to back its play on GSK's gene ther­a­py cast-offs

A few weeks ago, when Or­chard Ther­a­peu­tics fol­lowed its much buzzed about ne­go­ti­a­tions to carve out Glax­o­SmithK­line’s gene ther­a­py op­er­a­tions with a $150 mil­lion mega …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER